GSK seeks advice on planned Scottish respiratory API plant

By Gareth Macdonald contact

- Last updated on GMT

GSK plant in Montrose (source GSK)
GSK plant in Montrose (source GSK)

Related tags: Pharmacology, United kingdom, Pharmaceutical drug

GSK has asked Angus Council for advice as it prepares to submit a planning application for an API plant it intends to build at its site in Montrose, Scotland.

The UK pharmaceutical manufacturer confirmed it has sought guidance from the council’s planning department this week, telling us “we are at the scoping stage ahead of a full planning application​.”

Reports​ in the UK press suggest the new facility will produce salbutamol, the API in GSK's asthma treatment Ventolin.

The Montrose facility has been making drug ingredients for six decades. In 2003, GSK almost sold the facility to Akzo Nobel.

However, that deal fell through and GSK changed its plan a few years later​ after failing to find a replacement buyer.

At present the facility produces active ingredients for respiratory, HIV and vaccine products and employs over 450 staff.

Expansion plan

The firm first mooted the idea of building a new active pharmaceutical ingredient (API) facility at the site in July when it said it would spend £110m ($136m) on a manufacturing plant for respiratory active ingredients.

At the time GSK said: “A number of jobs will be created during the estimated three year construction phase.

Once on-line, the new state-of-the-art facility will provide long term security for the existing manufacturing related roles and will ensure a continued supply of respiratory medicine to millions of patients around the world​.”

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us


View more